Tests extra chemotherapy after first treatment in adults with advanced ovarian cancer
Tests extra chemotherapy after first treatment in adults with advanced ovarian cancer.
Key facts
- Who runs it
- Fudan University
- Where
- Shanghai, ChinaSee the site
- Trial code
- Registry title
- Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 590 people, planned
- Started
- 8 Oct 2021
- Expected to end
- Sept 2030
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Etoposide, Cyclophosphamide, Carboplatin/Cisplatin
- Record updated
- 27 July 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18-75 with stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer. The tumour must have normal BRCA1/2 genes, and the cancer must be in complete remission after surgery and first chemotherapy.
- Age
- 18 to 75 years
- Sex
- Women only
- Disease stage
- Epithelial ovarian, fallopian tube or primary peritoneal cancer, FIGO2018 stage III or IV. Complete remission after treatment and normal CA125.
- Earlier treatment
- Must have had optimal cytoreductive surgery with residual tumour of 1cm (0.4 in) or less, and no more than 9 cycles of paclitaxel plus platinum chemotherapy. The last chemotherapy was no more than 8 months ago.
- Biomarker or test result
- Tumour BRCA1/2 wild type, shown by a qualified centre test.
Main reasons for not taking part
- Primary or secondary immune deficiency
- A second primary cancer, with a few exceptions
- Severe heart, lung, liver or kidney failure
- Uncontrolled or active infection
- Mucinous adenocarcinoma or low grade carcinoma
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Female patients 18-75 years of age
- ECOG 0-2
- Histologically-confirmed epithelial ovarian or fallopian-tube cancer or primary peritoneal cancer
- FIGO2018 stage III/IV,
- Patients should have received optimal cytoreductive surgery with residual tumor ≤ 1cm and no more than 9 cycle paclitaxel + platinum chemotherapy achieved complete remission (accessed ) and normal CA125
- No more than 8 months after the last chemotherapy
- Adequate bone marrow and hepatic function at Screening:
- Hemoglobin ≥9 g/dL
- White blood cell count ≥3.0 × 109/L
- Absolute neutrophil count ≥1.5 × 109/L
- Platelet count ≥100 × 109/L
- AST (SGOT)/ALT (SGPT) ≤2.5 ULN
- Bilirubin <1.5 × ULN
- Creatinine <1.5 × ULN
- Ability and willingness to give written informed consent
- Tumor BRCA1/2 wilde type (qualified center test)
Who cannot take part
- Receipt of any other investigational medicinal product within the last 30 days before randomization
- Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, Ductal Carcinoma in Situ (DCIS), stage 1 grade 1 endometrial carcinoma, or other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥ 5 years
- Receipt of pelvic or abdominal radiotherapy
- Any uncontrolled medical condition that may put the patient at high risk during treatment
- Severe heart/ lung/ liver/ kidney failure
- uncontroled or active infection disease
- Primary or secondary immune deficiency
- Legal incompetence, limited legal competence, or detainment in an institution for official or legal reasons
- Mucinous adenocarcinoma, low grade carcinoma
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in China
- Wu XiaohuaShanghai, ChinaContact: zhong zheng, MD&PHDTaking people
About the trial
What the trial wants to find out
Ovarian cancer was mostly diagnosed at late stage (III/IV) with high rate of recurrence after first line of therapy by optimal cytoreductive sugery and 6cycle of TP chemotherapy. There is no standard maintainance therapy for BRCA1/2 wide-type ovarian cancer. We developed an adjuvant chemotherapy of "three steps" (ACTS). It is adding CTX+VP-16(second step) 6cycle and CTX+CBP(third steps) to firstline chemotherapy (first step). The aim of this study is to verify the effectivity and safety of ACTS in BRCA1/2 wide-type ovarian cancer patients.
The 2 groups in the trial
- Follow-upNo study treatment, for comparison
No interevention
- three steps chemotherapyTreatment being tested
Cyclophosphamide 400mg(250mg/m2)+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
Treatment: Etoposide, Cyclophosphamide, Carboplatin/Cisplatin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III,Randomized, Multi-center, Open Label Study of Adjuvant Chemotherapy of Three-step Regimens (ACTS) in BRCA1/2 Wide-type Stage III and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)
- Plain-language title
- Tests extra chemotherapy after first treatment in adults with advanced ovarian cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04520074, who can take part
- Record updated
- 27 July 2022